-+ 0.00%
-+ 0.00%
-+ 0.00%

Monte Rosa Therapeutics Shared Interim Data From An Ongoing Phase 1/2 Study Of MRT-2359 In Combination With Enzalutamide In Heavily Pretreated Patients With Metastatic Castration-resistant Prostate Cancer

Benzinga·12/16/2025 12:04:56
Listen to the news
  • In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, including 2 patients with RECIST responses and 2 with stable disease 
  • Combination of MRT-2359 and enzalutamide was generally well-tolerated with primarily Grade 1-2 adverse events
  • Company plans to initiate a new, signal-confirming Phase 2 study of MRT-2359 targeting AR mutant and AR signaling-dependent patients in 2026
  • Updated MRT-2359 data expected to be presented at ASCO Genitourinary Cancers Symposium in February 2026